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ABSTRACT  
Background: Molecular biomarkers, including isocitrate dehydrogenase 1 or 2 
(IDH1/2) mutation, 1p/19q codeletion and O6-methylguanine-DNA-methyltransferase 
(MGMT) promoter methylation, may improve prognostication and guide treatment 
decisions in patients with World Health Organization (WHO) anaplastic gliomas. At 
present, each marker is individually tested by distinct assays. Illumina Infinium® 
HumanMethylation450 BeadChip arrays (HM450) enable the determination of large-
scale methylation profiles and genome-wide DNA copy number changes. Algorithms 
have been developed to detect the glioma CpG island methylator phenotype (G-
CIMP) associated with IDH1/2 mutation, 1p/19q codeletion and MGMT promoter 
methylation using a single assay. 
Methods: Here, we retrospectively investigated the diagnostic and prognostic 
performance of these algorithms in comparison to individual marker testing and 
patient outcome in the biomarker cohort (n=115 patients) of the NOA-04 trial. 
Results: Concordance for IDH and 1p/19q status was very high: In 92% of cases, 
the HM450 and the reference data agreed. In discordant cases, survival analysis by 
Kaplan-Meier and Cox regression analyses suggested a more accurate assessment 
of the biological phenotype by the HM450 analysis. The HM450-derived MGMT-
STP27 model to calculate MGMT promoter methylation probability revealed this 
aberration in a significantly higher fraction of cases as conventional methylation-
specific PCR, with 87/91 G-CIMP tumors predicted as MGMT promoter-methylated. 
Pyrosequencing of discordant cases confirmed the HM450 assessment in 14/17 
cases. 
Conclusions: G-CIMP and 1p/19q codeletion are reliably detectable by HM450 
analysis and associated with prognosis in the NOA-04 trial. For MGMT, HM450 
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suggests promoter methylation in the vast majority of G-CIMP tumors, which is 
supported by pyrosequencing. 
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INTRODUCTION 
In recent years, insights into the biology of malignant gliomas have considerably 
increased, leading to the identification of several clinically useful biomarkers.1  In 
anaplastic astrocytic, oligodendroglial and oligoastrocytic gliomas of World Health 
Organization (WHO) grade III, three molecular parameters have been established 
and extensively characterized as either prognostic or predictive biomarkers. 
Combined deletion of chromosomal arms 1p and 19q (1p/19q codeletion), a hallmark 
of oligodendroglial tumors2, has emerged as a well-established prognostic marker in 
gliomas. Initially regarded as prognostic, this chromosomal aberration also predicted 
response to combined radio-chemotherapy in the long-term follow-up analyses of two 
large randomized clinical trials of patients with anaplastic oligodendroglial tumors, i.e. 
EORTC-26951 and RTOG-9402.3,4 Both trials consistently showed that mainly 
patients with 1p/19q codeleted tumors experience a clinically relevant survival benefit 
from combined treatment with radiotherapy and procarbazine, CCNU and vincristine 
(PCV). The molecular mechanisms linking 1p/19q codeletion to increased treatment 
sensitivity, however, are still poorly understood. In 2011, mutations of CIC (homolog 
of the drosophila gene capicua) on chromosome 19q and far-upstream element 
binding protein 1 (FUBP1) on 1p have been identified as potential mechanisms 
involved in the biology of 1p/19q codeleted gliomas.5 
Mutations in the isocitrate dehydrogenase 1 and 2 genes (IDH1/2) were first reported 
in a small fraction of glioblastoma6 and have since then been found at a variable 
incidence in many gliomas, mostly of WHO grade II and III.1 Over 70% of anaplastic 
gliomas carry an IDH mutation, with higher frequencies in oligodendroglial tumors7 
and a strong association with 1p/19q codeletion.8 IDH1/2 mutations are associated 
with the development of a specific epigenetic hypermethylator signature, the glioma 
CpG island methylator phenotype (G-CIMP).9,10 They also appear to originate from a 
N-O-D-14-00023R1 -6- 
distinct cell of origin.11 Randomized clinical trials and larger series have 
demonstrated a prolonged survival for patients with IDH1/2 mutant anaplastic 
gliomas.3,12,13 However, in most studies IDH mutations do not seem to confer benefit 
from a specific therapy (radio- or chemotherapy) and hence do not yet carry any 
predictive properties. 
Hypermethylation of the O-6-methylguanine-DNA methyltransferase (MGMT) 
promoter has been established to predict response to alkylating chemotherapy in 
glioblastoma.14,15 So far, real-time methylation-specific PCR is the only prospectively 
validated assay for determination of MGMT status in glioblastoma.16,17 
Mechanistically, modulation of alkylator sensitivity is well explained as MGMT 
catalyzes restoration of guanine from O-6-methylguanine, a major genomic lesion 
induced by alkylating agents. In anaplastic gliomas, however, the situation is more 
complex. Here, MGMT promoter methylation has been found to be a positive 
prognostic marker independent of treatment in non-overlapping series of anaplastic 
gliomas.12,18 A recent publication shed light on this issue, proposing an interaction 
between IDH mutation and MGMT methylation where in the presence of an IDH1/2 
mutation, MGMT promoter methylation is merely prognostic (independent of 
treatment), while in IDH1/2 wild type anaplastic gliomas, MGMT methylation 
specifically predicts benefit from alkylating chemotherapy.19 
Epigenome-wide analysis of DNA methylation patterns has received increasing 
attention in brain tumor research, deepening our insight into glioma biology and 
advancing the classification of tumors.10,20 Recently, algorithms have been developed 
which enable the assessment of all three aforementioned biomarkers from Illumina 
Infinium® HumanMethylation450 (HM450) data.10,20,21 Hybridization of tumor DNA to 
these arrays allows for methylation profiling of 450,000 CpG sites distributed across 
the human genome as well as genome-wide copy number profiling.20,22 Moreover, the 
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method is suitable for the analysis of routinely processed formalin-fixed and paraffin-
embedded (FFPE) tissue samples.22 In the present study, we aimed to assess the 
reliability and clinical value of HM450-based determination of G-CIMP, 1p/19q 
codeletion and MGMT promoter hypermethylation in the biomarker cohort of the 
NOA-04 trial. NOA-04 was designed to assess the optimal sequence of radio- and 
chemotherapy in patients with newly diagnosed anaplastic gliomas.12 In NOA-04, 
IDH1/2 mutations, 1p/19q codeletion and MGMT promoter methylation were 
prospectively centrally assessed and each marker demonstrated prognostic 
significance. The NOA-04 trial is hence well suited to investigate the diagnostic (and 
prognostic) accuracy of HM450-based molecular profiling. 
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METHODS 
Patients, evaluations and ethics 
The NOA-04 trial (NCT00717210) for patients with newly diagnosed anaplastic 
gliomas compared the efficacy and safety of initial radiotherapy, followed by 
chemotherapy (temozolomide or procarbazine, lomustine and vincristine) at 
progression or occurrence of unacceptable toxicity with the inverse sequence in 
patients with newly diagnosed anaplastic gliomas. In this trial, both sequences 
achieved similar results.12 Median follow-up time was 54 months. All patients 
consented to exploratory molecular analyses performed with study data and 
materials. The original phase III trial was approved by the Ethics Committee (EC) at 
the University of Tuebingen, Germany, and subsequently all local ECs of the 
participating clinical centers. NOA-04 enrolled patients after written informed consent 
including future molecular analyses at 39 sites in Germany. 
 
Molecular analyses 
IDH1 codon 132 and IDH2 codon 172 mutations (Sanger sequencing), 1p/19q 
codeletion (multiplex ligation-dependent probe assay, MLPA) and MGMT promoter 
methylation (methylation-specific PCR, MSP23) were centrally determined as 
described previously.12,19 For cases with discordance between IDH and G-CIMP 
status, IDH1R132H immunohistochemistry24 (in cases where sequencing indicated 
the presence of an R132H mutation) or DNA re-extraction and re-sequencing of IDH1 
codon 132 and IDH2 codon 172 was performed as described.19 MGMT 
pyrosequencing was performed using Qiagen PyroMark (Qiagen, Hilden, Germany) 
according to the manufacturer’s protocol and evaluated as given in Quillien et al.25 
TERT promoter mutations (C228 and C250) and ATRX status were previously 
determined.26,27 
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DNA extraction and Illumina Infinium® HumanMethylation450 BeadChip array 
analyses 
A tumor cell content of 80% or more was histologically verified prior to DNA 
extraction for each tumor specimen. For DNA extraction from FFPE tissue samples, 
the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) was used. Methylation analysis 
of 115 samples using the HM450 BeadChip (Illumina, San Diego, CA, USA) was 
performed at the DKFZ Genomics and Proteomics Core Facility (German Cancer 
Research Center, Heidelberg, Germany) with normalization to internal controls. 
 
Marker assessment 
Unsupervised hierarchical clustering of methylation data was performed as 
described.20 Briefly, probes (i) with a detection p-value > 0.05, (ii) targeting the X and 
Y chromosomes, (iii) containing a single nucleotide polymorphism within five base 
pairs of and including the CpG site and (iv) not mapping uniquely to the human 
reference genome (hg19), allowing for one mismatch, were removed. The 8000 
probes most variable by standard deviation were kept and unsupervised hierarchical 
clustering was performed. 
A logistic regression model to estimate the probability of MGMT promoter methylation 
from HM450 data was used as described by Bady et al21: From the normalized 
methylated (m) and unmethylated (u) signal intensities, the M-value was calculated: 
M-value = log2((m+1)/(u+1)). The probability of MGMT promoter methylation was 
calculated as logit(y) = 4.3215 + 0.5271 * M-value(cg12434587) + 0.9265 * M-
value(cg12981137). A probability cut-off at 0.358 was used for scoring unmethylated 
versus methylated. 
N-O-D-14-00023R1 -10- 
Copy number aberrations were detected from the HM450 data as described.20,22 
Copy number plots were manually analysed for 1p/19q codeletion. 
Statistics 
Fisher’s exact test was used to compare categorical data. To model MGMT 
methylation probability, logistic regression followed by receiver operating 
characteristic (ROC) curve analysis (using the pROC package28) was employed. For 
control of the familywise error rate, the Bonferroni procedure was used. Cox 
proportional hazards regression analysis was performed for survival analysis. A p-
value of < 0.05 was considered as statistically significant. All tests were two-sided. 
Analyses were carried out using R version 3.0.129 and Stata IC version 12.1 
(StataCorp LP, College Station, TX, USA). 
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RESULTS 
Baseline patient characteristics 
The present NOA-04 biomarker cohort comprised 115 of the 274 patients of the 
NOA-04 intention-to-treat (ITT) population, for which tumor DNA of sufficient amount 
and quality was available. Baseline characteristics of the biomarker cohort and the 
ITT population were similar (Table 1), except for an expected enrichment of patients 
with resection rather than biopsy because of tissue requirements for this analysis. As 
in the ITT population, time to treatment failure (TTF), the primary endpoint of the 
NOA-04 trial, was similar between both arms (log rank p = 0.94, Supplementary 
Figure 1). Importantly, in univariate Cox regression analysis, each of the three 
molecular biomarkers (IDH1/2 mutation, 1p/19q codeletion and MGMT promoter 
methylation) was significantly associated with survival in the biomarker cohort (Table 
2). 
 
G-CIMP (as a surrogate for IDH1/2 mutation) and 1p/19q codeletion status 
Unsupervised hierarchical clustering of the normalized HM450-based methylation 
data identified two main clusters as described previously. Ninety-one of 115 patients 
(79%) were grouped in the G-CIMP cluster, while 24 patients (21%) belonged to the 
non-G-CIMP cluster. As expected, presence of IDH1/2 mutations was strongly 
associated with the G-CIMP cluster (Table 3a, p < 0.001, Fisher’s exact test). 
However, in seven patients a G-CIMP phenotype was detected in the absence of an 
IDH1/2 mutation. Accordingly, sensitivity and specificity of G-CIMP status for IDH 
mutation were 98% and 72%, respectively. As depicted in the Kaplan-Meier curve in 
Figure 1, the discordant patients (IDH1/2 wild type, but G-CIMP positive) tended to 
have a survival more similar to IDH1/2 mutant / G-CIMP patients rather than IDH wild 
type / Non-G-CIMP patients although no definite conclusions can be drawn because 
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of the small number of patients. This observation is however substantiated in a Cox 
regression analysis including both IDH and G-CIMP status (Table 3b), in which only 
the G-CIMP status was significantly associated with time to treatment failure. The 
results for progression-free survival (PFS) were similar (data not shown), while for 
overall survival (OS), the small number of events precluded statistical testing. Upon 
re-assessment of the IDH status of these 7 patients by IDH1R132H 
immunohistochemistry or DNA re-extraction and re-sequencing, 6 / 7 cases were 
indeed IDH mutant. Further speaking to a correct assessment of the biological 
phenotype by the G-CIMP status is the observation that 3 out of these 7 cases had a 
1p/19q codeletion, which only occurs in IDH mutant tumors.8 On the other hand, 2 
cases with IDH mutation did not show the G-CIMP phenotype. For one of these, 
enough tissue of sufficient quality (vital tumor content > 80%) to re-extract DNA and 
re-sequence IDH1 codon 132 and IDH2 codon 172 was available: As expected, no 
mutation was found, confirming that this simple is indeed IDH wild type. 
Analysis of DNA copy-number data generated from the HM450 data revealed 
combined deletions of 1p and 19q in 41 of 115 patients (35%, example given in 
Figure 2a). As expected, the frequency of 1p/19q codeletion varied among the 
histological tumor types: It was rare in anaplastic astrocytoma (1 / 50) but rather 
common in tumors with at least an oligodendroglial component (25 / 45 
oligoastrocytomas and 15 / 20 oligodendrogliomas, p < 0.001, Fisher’s exact test). 
Agreement of 1p/19q status between MLPA and HM450 was observed in 91 / 99 
cases (Table 4a, p < 0.001, Fisher’s exact test). Sensitivity and specificity of HM450 
for detection of 1p/19q codeletion with MLPA set as standard were 84% and 98%, 
respectively. In 7 cases, the HM450 data did not show 1p/19q codeletion whereas 
MLPA indicated this lesion. Kaplan-Meier analysis (Figure 2b) revealed a similar 
clinical course for these discordant cases and patients whose tumors lacked the 
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1p/19q codeletion. Cox regression analysis including 1p/19q status from both 
techniques corroborated this, as again only 1p/19q status computed from HM450 
data was significantly associated with survival (Table 4b). An overview of clinical and 
pathological characteristics of all discordant cases is given in Supplementary Table 
4. 
 
MGMT promoter methylation 
Bady et al. proposed a logistic regression model (MGMT-STP27) to predict MGMT 
promoter methylation status from two CpG sites assayed both by the HM27 and 
HM450 BeadChips.21 Applying this algorithm to the NOA-04 dataset indicated that 99 
of 115 patients had a methylated MGMT promoter (86%), as opposed to 70 / 108 as 
assessed by MSP (65%). While the MGMT-STP27 algorithm indicated differential 
MGMT methylation in the Non-G-CIMP patients (Supplementary Table 1a), virtually 
all G-CIMP patients were considered to have a methylated MGMT promoter based 
on the HM450 algorithm (87 / 91). Cox regression analysis including both MSP and 
MGMT-STP27 status clearly demonstrated a closer association of MGMT status as 
per MGMT-STP27 with survival (Supplementary Table 5). Interestingly, the 
concordance of MGMT between the two assays was different for the histological 
tumor types with good concordance (15 / 17, 88%) in oligodendrogliomas and worse 
concordance in astrocytomas (19 / 31, 61%). 
Constructing a 95% confidence interval (based on the standard error of the fit) for 
each prediction resulted in 9 samples to be considered unclassifiable (as the 
confidence interval for methylation probability crossed the cut-off). To improve the 
prediction model for MGMT promoter methylation in the G-CIMP-positive tumors, we 
re-evaluated the 18 CpG sites within the MGMT 5'-CpG island originally investigated 
by Bady et al. in our cohort of 88 patients with G-CIMP positive tumors with known 
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MGMT promoter methylation status determined by MSP analysis. After Bonferroni 
adjustment to correct for type-I-error inflation, five CpG probes were significantly 
associated (as per univariate logistic regression) with MGMT methylation probability 
(Supplementary Table 2). Notably, this group contained both probes (cg12434587 & 
cg12981137) included in the MGMT-STP27 model. The remaining probes are located 
nearby to either of these two probes (Supplementary Figure 2). In a next step, we 
stepwise built prediction models from these probes. To limit overfitting, we used 
Akaike’s information criterion (AIC) with the default parameter (k = 2) for factor 
penalization. This approach yielded two models with similar AUC and AIC values 
(Table 5), one of them being the MGMT-STP27 (albeit with different regression 
coefficients and cut point). The ROC curves are shown in Figure 3, Supplementary 
Table 3 lists the predicted MGMT promoter methylation status for both models. Given 
the limited diagnostic accuracy of both models, MGMT methylation status as 
calculated from any of these two models was not significantly associated with 
outcome (Supplementary Table 3). To resolve the discrepancy between the MGMT-
STP27 and MSP findings, we performed MGMT pyrosequencing on all 17 discordant 
G-CIMP cases (methylated per MGMT-STP27, unmethylated per MSP), for which 
enough DNA of sufficient quality was left: Using a pre-defined mean methylation of 
8% as cut-off25, 14 samples were classified as MGMT methylated and only 3 as 
MGMT unmethylated.  
 
Relationship between IDH1/2 mutation/G-CIMP, 1p/19q codeletion and MGMT 
promoter methylation 
In this series, 93% (43 / 46) of all tumors with a 1p/19q codeletion (MLPA) carried an 
IDH mutation. Considering the HM450 data, all 41 samples with 1p/19q codeletion 
clustered in the G-CIMP group. Almost all 1p/19q codeleted tumors (HM450) 
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displayed a methylated MGMT promoter (37 / 41). In general, the frequency of 
MGMT promoter hypermethylation was higher in tumors with an IDH mutation: 73% 
(61 / 83) of tumors with an IDH1/2 mutation, as opposed to 36% (9 / 25) of the 
IDH1/2 wild type tumors had MGMT promoter methylation (see also19). For G-CIMP, 
1p/19q and MGMT (all assessed via the HM450), Cox regression demonstrated a 
prognostic impact independent of reference histology (Supplementary Table 6). 
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DISCUSSION 
For optimal management of patients with anaplastic gliomas, there is clinical need for 
reliable information on 1p/19q, IDH1/2 and MGMT status.30 Thus, molecular testing 
for these markers is increasingly being requested in neurooncology. Additional 
information derived from genome-wide analyses may be valuable, both for molecular 
subgrouping of tumors10,31 and identification of novel therapeutic targets.32 The 
Illumina Infinium® HumanMethylation450 BeadChip array platform, which has been 
shown to separate glioblastoma into six biologically meaningful molecular 
subgroups20, allows for the simultaneous assessment of these three most relevant 
biomarkers in anaplastic gliomas and additionally provides a powerful tool for future 
discoveries. In the present study, we have evaluated the diagnostic and prognostic 
reliability of biomarker assessment based on the HM450 array in a subgroup of 
patients of the NOA-04 trial and thus asked whether this technology - where available 
- may replace separate single marker testing. While G-CIMP and 1p/19q status were 
determined concordantly to the single marker tests, MGMT promoter methylation 
assessment differed considerably between MSP and the HM450-derived algorithm, 
especially in the G-CIMP tumors. Here, pyrosequencing of discordant cases 
suggested that most G-CIMP anaplastic glioma in fact carry a methylated MGMT 
promoter, as suggested by the HM450.  
For determination of IDH1/2 mutation, 1p/19q codeletion and MGMT promoter 
methylation status, a plethora of diagnostic methods exist without a uniformly agreed-
upon “gold standard”. Tissue requirements (both source and amount) as well as 
costs for testing constitute further issues to be considered. For the assessment of 
IDH mutation, sequencing of IDH1 codon 132 and IDH2 codon 172 as well as 
immunohistochemistry targeted against IDH1R132H are the most commonly used 
methods.33 While immunohistochemistry is a well-established technique with minimal 
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tissue requirements, it misses the (albeit rare) IDH mutations other than 
IDH1R132H.24 Sequencing, on the other hand, may miss low-level mutations. 
Fluorescence in situ hybridization (FISH) is nowadays probably the most commonly 
used assay to determine the 1p/19q status.34 It can easily be performed without the 
need for DNA extraction and hence avoiding dilution by normal cells. However, most 
commercially available probes are not able to distinguish partial and total deletions. 
Two smaller series have demonstrated a strong correlation between 1p/19q status as 
assessed by FISH and MLPA.35,36 For determination of the MGMT promoter 
methylation status, even a larger number of distinct diagnostic assays do exist, 
including MSP, pyrosequencing, methylation-sensitive high-resolution melting or 
MethyLight, and others.37 The original report of the predictive value of MGMT 
methylation in glioblastoma was performed using MSP.14 To date, real-time MSP is 
the only prospectively validated test for MGMT promoter methylation assessment in 
glioblastoma.16 However, an internationally accepted consensus about the most 
appropriate diagnostic method to be used for MGMT testing is still missing. 
Unfortunately, most other methodologies lack published validation according to 
guidelines for molecular diagnostics. In practice, the choice of method thus 
preferentially depends on the individual experience and equipment of each 
laboratory, e.g. availability of a pyrosequencer or real time PCR machine and the 
level of validation. 
Both for the IDH1/2 / G-CIMP and 1p/19q status, our comparative analyses of the 
NOA-04 biomarker cohort revealed only small subsets of cases showing discordant 
results when tested by HM450 arrays versus individual assays, i.e. IDH1/2 
sequencing and 1p/19q MLPA, respectively. In our series, 7 IDH1/2 wild type tumors 
by sequencing of codon 132 and 172, respectively, demonstrated G-CIMP (Table 
3a), which in part may be false-negative results due to the weak signal in the direct 
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Sanger sequencing.33 Consequently, re-examination of these 7 cases revealed that 6 
tumors actually carried an IDH mutation, as correctly predicted by the HM450 array.  
Conversely, of 2 cases with IDH mutation but without a G-CIMP, 1 case could be re-
analyzed and no IDH mutation was found, indicating that the initially reported IDH 
mutation was a false-positive result. Considering that IDH mutation causes the G-
CIMP9, this is not surprising and suggests that the other case will probably also be a 
false-positive IDH mutation.  Similarly, in the few discordant 1p/19q cases (1p/19q 
codeleted based on MLPA, 1p/19q intact as per HM450), the clinical course and 
pathological characteristics tended to accord to the HM450 data (Figure 2b, Table 
4b, Supplementary Table 4): Four of these 7 discordant cases were classified as 
anaplastic astrocytoma in reference histology, and of the remaining 3 cases, 1 case 
was classified as G-CIMP negative. In a previous analysis, we identified 3 cases 
carrying both ATRX (alpha-thalassemia/mental retardation syndrome X-linked) loss 
and 1p/19q codeletion, which should be mutually exclusive.27 Of these, 2 had an 
intact 1p/19q status as per HM450, while the third was not included in this cohort. 
TERT promoter mutations are strongly associated with the presence of 1p/19q 
codeletion in IDH mutant gliomas.38 Further supporting the HM450 1p/19q results, in 
6/7 cases where HM450-based 1p/19q analysis indicated no codeletion (while MLPA 
did), TERT promoter status was wild type, while in one case where HM450 indicated 
1p/19q codeletion as opposed to MLPA, a TERT promoter mutation was found. 
Taken together, the 1p/19q MLPA assessment of the initial NOA-04 trial likely 
resulted in a number of misclassified cases and particularly in an overestimation of 
the rate of 1p/19q codeleted tumors. This may be explained by the rather low 
threshold chosen in the initial MLPA assessment where two adjacent gene loci with a 
gene dosage ratio of less than 70% were considered as evidence of chromosome 
arm deletion. 
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In anaplastic gliomas, MGMT promoter methylation is merely prognostic and not 
predictive for a benefit from alkylating chemotherapy, most likely due to an interaction 
with the IDH1/2 mutation status.19 The MGMT-STP27 model with a reported AUC of 
0.97, a sensitivity of 0.97 and a specificity of 0.89 in G-CIMP negative tumors21, 
predicted MGMT promoter methylation in the vast majority of G-CIMP positive tumors 
(87 / 91) as opposed to the MSP (62 / 88 tumors methylated, three cases missing 
MGMT data). This strong association between MGMT methylation and IDH mutation 
has been noted before in the original report by Bady21 and is also shown by others 
using pyrosequencing.39 Cox regression analysis including both MSP and MGMT-
STP27 status clearly demonstrated a closer association of MGMT status as per 
MGMT-STP27 with survival (Supplementary Table 5). There was a clear 
association of the discordant MGMT assessment with histological subtype (high rates 
of discordant cases especially in astrocytomas). This may be a result of a lower 
sensitivity of MSP assessment in the more diffuse astrocytic tumors compared to 
often more compact oligodendroglial tumors and may also influence survival analysis. 
Using our cohort of 88 G-CIMP patients with known MGMT promoter methylation 
status as determined by MSP, we tried to build a new MGMT prediction model for G-
CIMP tumors based on the probes identified by Bady et al.21 Malley et al. defined two 
regions in the MGMT CpG island where hypermethylation was significantly 
associated with reduced MGMT mRNA expression (differentially methylated regions, 
DMR).40 Of these, pyrosequencing of DMR2 (chr10:131,265,496 – 131,265,626) 
demonstrated hypermethylation in almost all adult IDH mutant gliomas.39 This region 
is also covered by the forward and reverse MSP primers used in NOA-04 as well as 
two of the five cg probes on the HM450 significantly associated with MGMT 
methylation (cg02802904 & cg12981137) (Supplementary Figure 2). Importantly, 
cg12981137 is contained in the MGMT-STP27 model as well as in the two newly-
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fitted models. However, the two models for which Akaike’s AIC indicated the best fit 
resulted in an AUC of only 0.84 in ROC analysis (Table 5 and Figure 3). 
Consequently, both models were not significantly associated with survival 
(Supplementary Table 3). To resolve the discrepancy between the MGMT-STP27 
and MSP findings, we performed MGMT pyrosequencing on all 17 discordant G-
CIMP cases (methylated per MGMT-STP27, unmethylated per MSP) for which 
enough DNA of sufficient quality was left: Using a pre-defined mean methylation of 
8% as cut-off25, 14 samples were classified as MGMT methylated and only 3 as 
MGMT unmethylated, further supporting the notion that most IDH mutant / G-CIMP 
anaplastic gliomas carry a methylated MGMT promoter.  
Due to dense genomic coverage of the HM450, copy number analysis is possible in 
addition to methylation profiling as demonstrated.20 This allows the identification of 
multiple important and immediately relevant molecular aberrations1 using a single 
array, even retrospectively in archival tissue. Furthermore, while in the original NOA-
04 trial, some cases lacked molecular information, mostly 1p/19q status12, these 
parameters could be completely assessed for all patients based on the HM450 data. 
While the reported observations point towards a very good diagnostic and prognostic 
accuracy of the HM450 data, it is important to note that while this is a prospective, 
well documented and homogenous trial cohort, this comparison was not pre-
specified. Furthermore, the subset of patients investigated here is not necessarily 
representative for the entire NOA-04 trial cohort (even though the main prognostic 
factors and the equivalence of both treatment arms are recapitulated) and may be 
subject to bias, although all patients with sufficient tumor DNA were included.  
The HM450 approach thus accurately identified G-CIMP and 1p/19q status in this 
NOA-04 cohort. In discordant cases, the result from the HM450 data seemed to be 
clinically more useful as they appeared to better predict patient outcome and were 
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usually confirmed by reanalysis of discordant cases using different diagnostic tests. 
In addition to the biomarker information, the HM450 array yields epigenome-wide 
methylation data, which provide a powerful dataset for future discoveries.10,20 For 
MGMT methylation, the HM450 data indicates that most G-CIMP tumors carry a 
methylated MGMT promoter (as opposed to the MSP data), which is supported by 
other studies and pyrosequencing of the discordant cases. In conclusion, these NOA-
04-based results are encouraging. They should be verified in an independent trial, 
such as EORTC-26951 or CATNON.   
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FIGURE LEGENDS 
Figure 1: Time to treatment failure by G-CIMP/IDH status. The two samples Non-
G-CIMP / IDH mutant cases were omitted as KM-curves with two patients are not 
considered informative. 
Figure 2: 1p/19q status. (a) Example of a copy number plot generated from 
HumanMethylation450 data of a patient with 1p/19q codeletion. (b) Kaplan-Meier 
curve for TTF based on 1p/19q status (assessed by MLPA and 
HumanMethylation450). The 1 discordant case with 1p/19q codeletion as per 
HumanMethylation450 and intact 1p/19q status (MLPA) was omitted. 
Figure 3: MGMT promoter methylation prediction. ROC curves for the two models 
with the best fit (as per AIC). 
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 NOA-04 Biomarker Cohort NOA-04 Trial Cohort 
 RT 
(n = 65) 
PCV / TMZ 
(n = 50) 
RT 
(n = 139) 
PCV / TMZ 
(n = 135) 
Median age 
(range), years 
42 
(23 – 74) 
41.5 
(25 – 64) 
44 
(23 – 74) 
42 
(20 – 77) 
Astrocytoma, n 
Oligoastrocytoma, n 
Oligodendroglioma, n 
28 (43%) 
25 (38%) 
12 (19%) 
22 (43%) 
20 (40%) 
8 (17%) 
70 (50%) 
47 (34%) 
22 (16%) 
74 (55%) 
44 (32%) 
17 (13%) 
Resection, n 
Total 
Subtotal 
Biopsy 
 
31 (48%) 
33 (50.5%) 
1 (1.5%) 
 
22 (44%) 
27 (54%) 
1 (2%) 
 
53 (38%) 
61 (44%) 
25 (18%) 
 
47 (35%) 
57 (42%) 
31 (23%) 
1p/19q co-deletion, n 
Yes 
No 
Information missing 
 
27 (46%) 
31 (54%) 
7 
 
19 (46%) 
22 (54%) 
9 
 
41 (43%) 
54 (57%) 
44 
 
33 (38%) 
53 (62%) 
49 
MGMT promoter, n 
Methylated 
Unmethylated 
Information missing 
 
37 (60%) 
24 (40%) 
4 
 
33 (70%) 
14 (30%) 
3 
 
59 (57%) 
44 (43%) 
36 
 
64 (64%) 
35 (36%) 
36 
IDH mutation, n 
Yes 
No 
Information missing 
 
48 (78%) 
13 (22%) 
4 
 
35 (74%) 
12 (26%) 
3 
 
65 (66%) 
33 (34%) 
41 
 
68 (70%) 
29 (30%) 
38 
RT, radiotherapy; PCV, procarbazine, CCNU & vincristine; TMZ, temozolomide 
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Table 2. Univariate Cox regression in the NOA-04 biomarker cohort 
Variable Hazard Ratio 95% CI p 
IDH mutation vs. 
wild type 
0.2 0.1 - 0.37 < 0.001 
1p/19q codeletion, 
yes vs. no 
0.26 0.13 - 0.55 < 0.001 
MGMT methylated 
vs. unmethylated 
0.5 0.28 - 0.92 0.026 
CI, confidence interval; IDH, isocitrate dehydrogenase; MGMT, O6-methylguanine-
DNA-methyltransferase 
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Formatiert: Englisch (USA)Table 3: IDH and G-CIMP status as per NOA-04 assessment and HM450. 
A) Tabulation of IDH mutation and G-CIMP status 
 G-CIMP Non-G-CIMP 
IDH mutant 81 2 
IDH wild type 7 18 
 
B) Cox regression for IDH and G-CIMP status 
Variable Hazard Ratio 95% CI p 
IDH mutation vs. 
wild type 
0.45 0.15 - 1.3 0.14 
G-CIMP vs. 
Non-G-CIMP 
0.32 0.1 - 0.94 0.038 
CI, confidence interval; G-CIMP, glioma CpG island methylator phenotype; 
IDH, isocitrate dehydrogenase  
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Formatiert: Englisch (USA)Table 4: 1p/19q status by MLPA and HM450 BeadChip 
A) Tabulation of 1p/19q status 
 1p/19q codeleted 
(HM450) 
1p/19q intact (HM450) 
1p/19q codeletion 
(MLPA) 
39 7 
1p/19q intact (MLPA) 1 52 
 
B) Cox regression for 1p/19q status 
Variable Hazard Ratio 95% CI p 
1p/19q codeletion, 
yes vs. no (MLPA) 
0.875 0.28 - 2.69 0.817 
1p/19q codeletion, 
yes vs. no (HM450) 
0.22 0.06 - 0.79 0.021 
CI, confidence interval; HM450, Illumina HumanMethylation450 BeadChip; 
MLPA, multiplex ligation-dependent probe assay 
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Table 5: MGMT methylation probability models 
Model formula Cutpoint Sens. Spec. AUC AIC 
logit(y) = 1.3669 + (0.5305 
* cg14194875) + (0.5691 * 
cg12981137) 
0.674 0.838 0.807 0.848 86.656 
logit(y) = 1.6768 + (0. 
0.3427 * cg12434587) + 
(0.6353 * cg12981137) 
0.765 0.709 0.884 0.84 86.686 
Sens., sensitivity; Spec., specificity; AUC, area under the curve; AIC, An information 
criterion 
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SUPPLEMENTARY INFORMATION 
 
Assessing CpG island methylator phenotype, 1p/19q codeletion and MGMT 
promoter methylation from epigenome-wide data in the biomarker cohort of the 
NOA-04 trial 
 
Benedikt Wiestler, David Capper, Volker Hovestadt, Martin Sill, David TW Jones, 
Christian Hartmann, Joerg Felsberg, Michael Platten, Wolfgang Feiden, Kathy 
Keyvani, Stefan M Pfister, Otmar D Wiestler, Richard Meyermann, Guido 
Reifenberger, Thorsten Pietsch, Andreas von Deimling, Michael Weller, Wolfgang 
Wick
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SUPPLEMENTARY FIGURE 1: TTF by treatment. Kaplan-Meier curves for TTF by 
treatment arm. 
SUPPLEMENTARY FIGURE 2: Overview of the MGMT CpG island. Genomic 
position of the five cg probes significantly associated with MGMT methylation, the 
MSP forward (MSPf) and reverse (MSPr) primers, differentially methylated regions 1 
& 2 (DMR1, DMR2) and the region pyrosequenced (PySeq) by Mulholland et al1 
(http://genome.ucsc.edu). 
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SUPPLEMENTARY TABLE 1: MGMT promoter methylation assayed by MSP and 
HM450 by G-CIMP status 
A) Non-G-CIMP (n = 20) 
 MGMT methylated 
(HM450) 
MGMT unmethylated 
(HM450) 
MGMT methylated 
(MSP) 
6 2 
MGMT unmethylated 
(MSP) 
3 9 
 
B) G-CIMP (n = 88) 
 MGMT methylated 
(HM450) 
MGMT unmethylated 
(HM450) 
MGMT methylated 
(MSP) 
61 1 
MGMT unmethylated 
(MSP) 
23 3 
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SUPPLEMENTARY TABLE 2: Probes evaluated for correlation with MGMT 
methylation 
Probe p (Log. R.) p (Bonf. adj.) AUC (ROC) 
cg12981137 6.85E-05 0.00123229 0.82444169 
cg14194875 0.00011347 0.00204248 0.8101737 
cg12434587 0.00024433 0.00439802 0.77915633 
cg02802904 0.00044483 0.00800691 0.76674938 
cg00618725 0.0005937 0.01068664 0.75496278 
cg12575438 0.03191845 0.57453215 0.66191067 
cg26950715 0.85340664 1 0.53970223 
cg02330106 0.09707108 1 0.53908189 
cg02022136 0.1300395 1 0.60545906 
cg23998405 0.11472322 1 0.60297767 
cg01341123 0.65465199 1 0.48883375 
cg25946389 0.1040175 1 0.5825062 
cg16215402 0.84916291 1 0.5353598 
cg18026026 0.51003379 1 0.55955335 
cg05068430 0.70899511 1 0.48138958 
cg19706602 0.27974073 1 0.57816377 
cg02941816 0.32090352 1 0.55955335 
cg26201213 0.32928739 1 0.45409429 
Log. R., logistic regression; Bonf. adj., Bonferroni adjusted; AUC, area under the 
curce; ROC, receiver operating characteristic 
Probes in bold are those comprising the model presented by Bady et al.2 
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SUPPLEMENTARY TABLE 3: MGMT status as per MSP and fitted models and Cox 
regression 
A) Model 1: cg14194875 + cg12981137 
 MGMT methylated 
(HM450) 
MGMT unmethylated 
(HM450) 
MGMT methylated 
(MSP) 
52 10 
MGMT unmethylated 
(MSP) 
5 21 
Cox variable Hazard Ratio 95% CI p 
MGMT M vs. U 0.92 0.39 – 2.14 0.85 
 
B) Model 2: cg12434587 + cg12981137 
 MGMT methylated 
(HM450) 
MGMT unmethylated 
(HM450) 
MGMT methylated 
(MSP) 
44 18 
MGMT unmethylated 
(MSP) 
3 23 
Cox variable Hazard Ratio 95% CI p 
MGMT M vs. U 0.82 0.37 – 1.81 0.62 
M, methylated MGMT promoter; U, unmethylated MGMT promoter 
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SUPPLEMENTARY TABLE 4: Overview of clinical and pathological characteristics 
of all discordant cases (IDH / G-CIMP and 1p/19q) as per NOA-04 assessment and 
HM450 data. 
Histology IDH G-CIMP MLPA HM450 
codel 
TERT ATRX 
AA mut - intact intact wt expr 
AA mut + codel intact mut expr 
AO mut + codel intact wt  
AA wt + intact intact   
AA wt +  intact wt loss 
AOA wt + codel codel  loss 
AA mut + codel intact wt loss 
AA mut + codel intact wt expr 
AO wt + codel codel   
AOA wt +  intact wt loss 
AA mut + codel intact wt loss 
AO mut + intact codel mut expr 
AA wt +  intact wt loss 
AO mut - codel intact wt expr 
AO mut + codel intact wt expr 
AOA wt + codel codel mut expr 
AA, anaplastic astrocytoma; AOA, anaplastic oligoastrocytoma; AO, anaplastic 
oligodendroglioma; mut, mutant; wt, wild type; codel, codeletion; expr, expression 
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SUPPLEMENTARY TABLE 5: Cox regression for MGMT status 
Variable Hazard Ratio 95% CI p 
MGMT, 
M vs. U (MSP) 
0.8 0.39 - 1.64 0.546 
MGMT, 
M vs. U (HM450) 
0.19 0.08 - 0.46 < 0.001 
CI, confidence interval; HM450, Illumina HumanMethylation450 BeadChip; 
MSP, methylation-specific PCR; M, methylated; U, unmethylated 
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SUPPLEMENTARY TABLE 6: Cox regression analyses for the association of G-
CIMP, 1p/19q and MGMT status (all per HM450) independent of reference histology 
and median time to treatment failure (TTF) in molecular subgroups. 
A) G-CIMP and reference histology 
Variable Hazard Ratio 95% CI p 
AO vs. AA 0.8 0.37 - 1.76 0.588 
AOA vs. AA 0.56 0.28 - 1.12 0.1 
G-CIMP, yes vs. no 0.17 0.09 – 0.32 < 0.001 
 
B) 1p/19q and reference histology 
Variable Hazard Ratio 95% CI P 
AO vs. AA 2.22 0.91 - 5.41 0.079 
AOA vs. AA 0.82 0.41 - 1.62 0.56 
1p/19q codeletion, 
yes vs. no 
0.16 0.06 – 0.39 < 0.001 
 
C) MGMT and reference histology 
Variable Hazard Ratio 95% CI P 
AO vs. AA 0.57 0.26 - 1.24 0.157 
AOA vs. AA 0.41 0.21 - 1.12 0.076 
MGMT, M vs. U 0.18 0.08 – 0.37 < 0.001 
CI, confidence interval; AA, anaplastic astrocytoma; AOA, anaplastic 
oligoastrocytoma; AO, anaplastic oligodendroglioma; M, methylated; U, 
unmethylated 
 
 
N-O-D-14-00023R1 SUPPLEMENT -9- 
 
D) Median TTF in molecular subgroups based on G-CIMP and 1p/19q status 
Group Median TTF (95% CI), days 
G-CIMP negative 
(n = 24) 
496 (326 – 1080) days 
G-CIMP positive, 
1p/19q intact 
(n = 50) 
1758 (793 – not reached) days 
G-CIMP positive, 
1p/19q codeleted 
(n = 41) 
Not reached (1840 – not reached) days 
CI, confidence interval 
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